Pfizer shutters vaccine sales business in China after Prevenar setback

Carly Helfand

As it beefs up its vaccines , 's looking to bolster revenue from the top-selling family of shots. But on that front, it's come up against a roadblock in –and so it's shutting down its vaccines marketing there.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS